Saturday, October 12, 2024 from 1:45 PM to 3:15 PM MST at Convention Center North Building / Meeting Room 131
Available for 1.50 hours of CPE creditActivity Number: 0217-0000-24-133-L01-PActivity Type: A Knowledge-Based ActivityThis session aims to address four objectives and will provide a review of the background for of recent literature related to the treatment and monitoring of autonomic dysreflexia (AD) versus paroxysmal sympathetic hyperactivity (PSH), previously known as dysautonomia, in pediatric patients. The target audience of this session is all pediatric pharmacists in both the inpatient and outpatient settings who care for infants and children that are complex, chronic patients. It is the purpose of this session to provide the pharmacist with the knowledge and tools to appropriately treat these high-risk patients.
Learning Objectives1. Define autonomic dysreflexia (AD) and paroxysmal sympathetic hyperactivity (PSH).
2. Review the various therapies for AD and PSH.
3. Discuss the controversies and considerations surrounding therapies for AD and PSH.
4. Describe the role of pharmacists in the care of children with complex needs.
| Moderator: | Michael Raschka, Pharm.D., BCPPS, DPLA | | Clinical Coordinator and Residency Program Director
Children's Minnesota
Minneapolis, Minnesota | View Biography |
|
Management of Autonomic Dysreflexia (AD)1:45 PM to 2:15 PM | Speaker: | Kaitlynn Hughes, Pharm.D., BCPPS | | Pediatric Clinical Pharmacy Specialist
Hoop's Family Children's Hospital
Huntington, WV | View Biography |
|
|
Management of Paroxysmal Sympathetic Hyperactivity (PSH)2:15 PM to 2:45 PM | Speaker: | Patrik Miller, Pharm.D., BCPPS | | Patient Care Pharmacist - Neurology and Complex Care
Nationwide Children's Hospital
Columbus, OH | View Biography |
|
|
Patient Case and Pro-Con Debate (Panel)2:45 PM to 3:15 PM |